HighMark Wealth Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

HighMark Wealth Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,000	Closed	-$600	–	600
2023 Q3	$600	Hold	1,000	–	–	﹤0.01%	527
2023 Q2	$1.3K	Hold	1,000	–	–	﹤0.01%	490
2023 Q1	$1.76K	Hold	1,000	–	–	﹤0.01%	512
2022 Q4	$3.14K	Hold	1,000	–	–	﹤0.01%	395
2022 Q3	$5K	Hold	1,000	–	–	﹤0.01%	345
2022 Q2	$4K	Hold	1,000	–	–	﹤0.01%	382
2022 Q1	$6K	Hold	1,000	–	–	﹤0.01%	349
2021 Q4	$8K	Hold	1,000	–	–	0.01%	298
2021 Q3	$9K	Hold	1,000	–	–	0.01%	269
2021 Q2	$12K	Hold	1,000	–	–	0.01%	238
2021 Q1	$13K	Hold	1,000	–	–	0.01%	206
2020 Q4	$16K	Hold	1,000	–	–	0.01%	178
2020 Q3	$9K	Hold	1,000	–	–	0.01%	249
2020 Q2	$9K	Sell	1,000 -143	-13%	-$1.33K	0.01%	224
2020 Q1	$7K	Buy	1,143 +143	+14%	+$1.06K	0.01%	189
2019 Q4	$8K	Buy	+1,000	New	+$9.2K	0.01%	249

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HighMark Wealth Management's SGMO Position: Q4 2023 in Review

HighMark Wealth Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2023, closing a stake of 1,000 shares — an estimated $600 sold.

HighMark Wealth Management first reported a position in SGMO in Q4 2019 and held it in 16 quarters. The position peaked at $16K in Q4 2020. 130 funds tracked by Wall St. Rank hold SGMO as of Q4 2023.

HighMark Wealth Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
HighMark Wealth Management sold 1,000 SANGAMO THERAPEUTICS INC shares in Q4 2023, an estimated $600.
HighMark Wealth Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 16 quarters.
HighMark Wealth Management's SANGAMO THERAPEUTICS INC position peaked at $16K in Q4 2020.
130 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2023.

Based on HighMark Wealth Management's 13F filing for Q4 2023, filed 23 Jan 2024.